stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) EPS (diluted)
Denali Therapeutics Inc.'s EPS (diluted) for fiscal 2025 was −$2.97, compared with −$2.57 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.73. Over the past ten years it has ranged from −$13.49 (fiscal 2016) to $0.63 (fiscal 2020); the current reading is higher than 36% of that period. Denali Therapeutics Inc. ranks 299th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.97 | — |
| FY2024 | −$2.57 | — |
| FY2023 | −$1.06 | — |
| FY2022 | −$2.60 | — |
| FY2021 | −$2.39 | — |
| FY2020 | $0.63 | — |
| FY2019 | −$2.07 | — |
| FY2018 | −$0.39 | — |
| FY2017 | −$5.89 | — |
| FY2016 | −$13.49 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.37 | — |
| Jun 2026 | −$0.68 | — |
| Mar 2026 | −$0.69 | — |
| Dec 2025 | −$0.73 | — |
| 35 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | −$1.67 |
| DNLI Denali Therapeutics Inc. | −$1.73 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| VRDN Viridian Therapeutics, Inc. compare | −$3.37 |
| CELC Celcuity, Inc. compare | −$4.30 |
| IDYA IDEAYA Biosciences, Inc. compare | −$4.49 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$15.19 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on DNLI
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement